Drtherapeutics International Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 23-10-2024
- Paid Up Capital ₹ 0.10 M
as on 23-10-2024
- Company Age 6 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.10 M
as on 23-10-2024
- Revenue -4.78%
(FY 2023)
- Profit -91.72%
(FY 2023)
- Ebitda -27.81%
(FY 2023)
- Net Worth 1.97%
(FY 2023)
- Total Assets 0.93%
(FY 2023)
About Drtherapeutics International Pharmaceuticals
The Company is engaged in the Fmcg Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹2.10 M.
Kamal Durwas and Leena Puri serve as directors at the Company.
- CIN/LLPIN
U74999PN2018PTC175028
- Company No.
175028
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Feb 2018
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Drtherapeutics International Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kamal Durwas  | Director | 21-Feb-2019 | Current |
| Leena Puri | Director | 28-Feb-2018 | Current |
Financial Performance of Drtherapeutics International Pharmaceuticals.
Drtherapeutics International Pharmaceuticals Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 4.78% decrease. The company also saw a substantial fall in profitability, with a 91.72% decrease in profit. The company's net worth moved up by a moderate rise of 1.97%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Drtherapeutics International Pharmaceuticals?
In 2023, Drtherapeutics International Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Idbi Bank Limited Creation Date: 22 Sep 2020 | ₹2.10 M | Open |
How Many Employees Work at Drtherapeutics International Pharmaceuticals?
Unlock and access historical data on people associated with Drtherapeutics International Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Drtherapeutics International Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Drtherapeutics International Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
